health

US judge approves Bayer's $7.25 billion cancer settlement

US judge approves Bayer's $7.25 billion cancer settlement

Bayer could end years of costly lawsuits in the US over claims that its Roundup weedkiller causes cancer. Tens of thousands of people could now receive compensation, although some lawyers say the payments are too low.

A US judge on Friday approved German chemical giant Bayer's $7.25 billion (€6.60 billion) settlement of lawsuits claiming its Roundup weedkiller causes cancer.

Judge Timothy Boyer in the US state of Missouri ruled that the agreement was "fair, reasonable, and adequate."

The decision could help Bayer end years of costly legal battles over Roundup, which the company acquired when it bought US weedkiller producer Monsanto in 2018.

"The court's final approval is a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation," Bayer CEO Bill Anderson said.

The agreement covers tens of thousands of people who say they developed non-Hodgkin lymphoma, a type of blood cancer, after using Roundup.

It also covers people who may be diagnosed with the disease in the future after previous exposure to the weedkiller.

Bayer will pay up to $7.25 billion into a special fund over the next 21 years.

Individual payments are expected to average between $10,000 and $165,000. The amount will depend on factors including the patient's age, the severity of the illness and how long they were exposed to Roundup.

Some lawyers representing cancer patients have criticized the payments as too low.

But the judge rejected their objections, saying that further delays could leave seriously ill patients waiting years for compensation.

Christopher Seeger, a lawyer representing cancer patients, welcomed the decision.

"Today's final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice," he said.

The settlement follows a major victory for Bayer at the US Supreme Court in June.

The court ruled that Bayer could not be sued under state laws for failing to put cancer warnings on Roundup packaging.

The judges argued that US federal rules did not require such warnings and that individual states could not impose additional labeling requirements.

The decision made it much harder for cancer patients to win lawsuits against Bayer.

In October, a Missouri jury also ruled in Bayer's favor in a separate Roundup cancer case.

However, some legal battles continue. Around 200 cases are still being fought in federal courts outside the new settlement, according to Bayer.

Monsanto introduced Roundup in 1974. Its main ingredient, glyphosate, became one of the world's most widely used weedkillers.

Farmers use Roundup to kill weeds without damaging crops that have been genetically modified to survive the chemical. It has also been widely used in private gardens and on lawns.

Bayer inherited the legal problems surrounding Roundup when it bought Monsanto for $63 billion in 2018.

Since then, around 200,000 claims have been made against Bayer by people who believe the weedkiller caused their cancer.

The company already agreed to a $10.9 billion settlement in 2020. However, it failed to secure approval for a separate agreement covering future cases.

Some lawsuits have resulted in huge payouts, including a $2.1 billion award to plaintiffs in Georgia.

Bayer has already set aside $16 billion for Roundup-related legal costs. Its shares have fallen by 46% since the Monsanto takeover.

The company has also removed glyphosate from newer versions of Roundup sold to private consumers in the United States.

Scientists and regulators disagree about whether glyphosate causes cancer.

In 2015, the World Health Organization's cancer research agency classified the chemical as "probably carcinogenic" to humans.

However, the US Environmental Protection Agency says glyphosate is unlikely to cause cancer when used as directed.

Bayer has repeatedly denied that Roundup causes cancer, pointing to scientific studies and regulatory approvals.

The debate intensified last year when a major scientific study that had supported Roundup's safety for decades was withdrawn.

The journal that published it cited serious problems, including missing cancer research and previously undisclosed involvement by Monsanto employees.

The withdrawal raised further questions about the influence of chemical companies on scientific research.

  • cancer
  • judge
  • bayer
  • settlement
  • lawsuit
  • claim
  • weedkiller
  • ten

Summaries and tags are generated automatically. Stay informed with VidiaNews.

Related news

Judge approves $7.25bn Bayer payout to settle claims that Roundup causes cancer
health

Judge approves $7.25bn Bayer payout to settle claims that Roundup causes cancer

German company faced 65,000 claims from people who said they developed cancer after using weedkiller A Missouri judge on Friday approved Bayer’s $7.25bn settlement of lawsuits ⁠alleging that its weedkiller ​Roundup causes cancer, potentially resolving litigation that has weighed on the German company for close to a decade. Judge Timothy Boyer of a state court in St Louis ⁠found the settlement “fair, reasonable and adequate”.

Read →
Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’
health

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

Cancer undetectable for one in 12 patients in daraxonrasib trial, while nearly all participants’ tumours stopped growing A pill that can shrink and potentially eliminate pancreas tumours is being hailed as the biggest breakthrough treatment for the cancer in decades. In one in 12 of the patients given the drug, daraxonrasib, during a trial, the cancer became undetectable, and the tumours stopped growing in almost all of the 61 patients.

Read →
Judge bans Trump’s restrictions on HIV funds for transgender patients
health

Judge bans Trump’s restrictions on HIV funds for transgender patients

The Trump administration cannot impose restrictions barring healthcare providers that receive certain federal HIV-treatment ⁠funds from acknowledging the gender identity ⁠of their transgender patients ​or from providing them with gender-affirming care, a federal judge ruled on Thursday. US district judge William Young in Boston sided with a group of national HIV medical associations and ⁠healthcare providers that challenged grant funding conditions imposed by the administration last year after Trump signed an executive order prohibiting federal funding for what he calls “gender ideology”.

Read →
Bacterial toxin produced by E coli leading suspect in rise in bowel cancer among under-50s
health

Bacterial toxin produced by E coli leading suspect in rise in bowel cancer among under-50s

Scientists tell Commons committee that exposure to colibactin in early life is a potential driver of early onset colorectal cancer Exposure to a bacterial toxin in early life has emerged as a leading suspect in the rise of bowel cancer amongs those under 50, MPs have heard. Cases of early onset bowel cancer have doubled in many countries in the past two decades, and while rising obesity and a fall in physical activity are contributors, researchers believe other factors must also be involved.

Read →